| Title: |
Impact of Metformin Use on Liver Function Tests in Diabetic Patients With Suspected Non-Alcoholic Fatty Liver Disease (NAFLD): A Cross-Sectional Analysis. |
| Authors: |
Asghar, Adeel; Azam, Amina; Imran, Muhammad Mustafa; Tariq, Muhammad Rohail; Sohail, Muhammad Adil; Tariq, Zainab; Mushtaq, Umer; Khalid, Fajar |
| Source: |
Cureus: Journal of Medical Science; Aug2025, Vol. 17 Issue 8, p1-6, 6p |
| Subject Terms: |
Metformin; Non-alcoholic fatty liver disease; Liver function tests; Cross-sectional method; Liver enzymes; Diabetes |
| Abstract: |
Background: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent among patients with type 2 diabetes mellitus (T2DM) and is often associated with elevated liver enzymes. Objective: To assess the impact of metformin use on liver function tests in diabetic patients with clinically suspected NAFLD. Methods: This was a cross-sectional analytical study conducted at Jinnah Hospital, Lahore, Pakistan, from July 2024 to December 2024. A total of 185 adult patients were enrolled in the study. Non-probability consecutive sampling was used to recruit participants who met the inclusion criteria. Demographic data, including age, gender, body mass index (BMI), and duration of diabetes, were recorded. Clinical records were reviewed to document metformin use (yes/no), dosage, and duration. Results: Out of 185 patients, 115 (62.2%) were metformin users and 70 (37.8%) were non-users. Metformin users had significantly lower mean alanine aminotransferase (ALT) (41.3 ± 14.6 IU/L vs. 54.7 ± 18.2 IU/L; p < 0.001) and aspartate aminotransferase (AST) levels (35.2 ± 12.4 IU/L vs. 44.6 ± 15.7 IU/L; p = 0.002) compared to non-users. No significant differences were observed in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) levels. Elevated ALT and AST were significantly less frequent in metformin users (p < 0.01). A weak inverse correlation was observed between metformin dose and ALT levels (r = -0.19, p = 0.043). Conclusion: It is concluded that metformin use is associated with improved liver enzyme profiles in diabetic patients with suspected NAFLD. These findings suggest a potential hepatoprotective role for metformin, warranting further longitudinal studies to explore its impact on liver histology and long-term hepatic outcomes. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Cureus: Journal of Medical Science is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |